AN2 Therapeutics, Inc.

NasdaqGS:ANTX Rapporto sulle azioni

Cap. di mercato: US$38.8m

AN2 Therapeutics Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Eric Easom

Amministratore delegato

US$3.3m

Compenso totale

Percentuale dello stipendio del CEO17.2%
Mandato del CEO5yrs
Proprietà del CEO4.1%
Durata media del management5yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Nov 21
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Jul 04
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Dec 05
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Aug 20
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

May 09
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Feb 03
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

Oct 21
We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

AN2 Therapeutics secures $17.8M contract from NIH

Sep 29

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Jul 01
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric Easom rispetto agli utili di AN2 Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$66m

Dec 31 2023US$3mUS$575k

-US$65m

Sep 30 2023n/an/a

-US$60m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$49m

Dec 31 2022US$3mUS$481k

-US$43m

Sep 30 2022n/an/a

-US$40m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$2mUS$377k

-US$28m

Compensazione vs Mercato: La retribuzione totale di Eric ($USD 3.34M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 653.78K ).

Compensazione vs guadagni: La retribuzione di Eric è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Eric Easom (56 yo)

5yrs

Mandato

US$3,342,848

Compensazione

Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Eric Easom
Co-Founder5yrsUS$3.34m4.06%
$ 1.6m
Joseph Zakrzewski
Co-Founder & Chairman of the Board7.5yrsUS$179.64k1.69%
$ 655.3k
Lucy Day
CFO, Principal Financial Officer & Principal Accounting Officer5yrsUS$1.52m0.010%
$ 4.1k
George Talbot
Co-Founder & Senior Clinical Advisorno dataNessun datoNessun dato
Michael R. Alley
Co-Founder & Head of Biologyno dataNessun datoNessun dato
Joshua Eizen
Chief Legal Officer2.2yrsUS$1.66mNessun dato
Sanjay Chanda
Chief Development Officer5yrsNessun dato0.0025%
$ 954.4
Stephen Prior
Chief Strategy Officerno dataNessun dato0.026%
$ 10.0k

5.0yrs

Durata media

60.5yo

Età media

Gestione esperta: Il team dirigenziale di ANTX è esperto e expertise (durata media dell'incarico 5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Eric Easom
Co-Founder5yrsUS$3.34m4.06%
$ 1.6m
Joseph Zakrzewski
Co-Founder & Chairman of the Board7.5yrsUS$179.64k1.69%
$ 655.3k
Melvin Spigelman
Independent Director2.8yrsUS$145.64k0%
$ 0
Patricia Martin
Independent Director3.6yrsUS$153.14k0%
$ 0
Margaret FitzPatrick
Lead Independent Director2.5yrsUS$142.14k0%
$ 0
Robin Readnour
Independent Director5yrsUS$146.14k0%
$ 0
Stephanie Wong
Independent Director3.6yrsUS$157.14k0%
$ 0
Kabeer Aziz
Independent Director5yrsUS$145.64k0%
$ 0
Gilbert Marks
Independent Director4.8yrsUS$145.64k0.076%
$ 29.7k

4.8yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ANTX sono considerati esperti (durata media dell'incarico 4.8 anni).